GILD
GILEAD SCIENCES, INC.
Nasdaq: GILD · Foster City, CA · Healthcare
$121.83-3.67 (-2.92%)Closed
Market Cap$151.35B
Cash$5.43Bmost recent
Runwayprofitable
P/E (TTM)18.0EPS $6.78
52-Wk Range$103.92 – $154.92
Avg Volume7.0M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$121.83+98.9%
Pipeline

Drug candidates sponsored by GILEAD SCIENCES · ClinicalTrials.gov

74 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Truvada
HIV Infections
Completed
2007-07past
1
Phase 4Truvada + Kaletra
HIV-1
Completed
2009-09past
1
Phase 4Tenofovir DF
Hepatitis B
Terminated
2018-02-28past
1
Phase 4B/F/TAF
HIV-1-infection
Completed
2025-01-29past
1
Phase 4F/TAF (High Dose Tablet)
HIV-1-infection
Recruiting
2034-03
1
Phase 4liposomal amphotericin B (AmBisome®)
Fungal Infection
Terminated—1
Phase 4Viread
HIV Infections
Completed—1
Phase 3Emtricitabine (FTC)
HIV Infections
Completed
2005-02past
1
Phase 3Ambrisentan
Pulmonary Hypertension
Completed
2008-07past
1
Phase 3AZLI 75 mg two times a day (BID)/ three times a day (TID)
Cystic Fibrosis
Completed
2008-11past
1
Phase 3AZLI 75 mg three times daily (TID)
Cystic Fibrosis+2 more
Completed
2009-06past
1
Phase 3COBI
HIV+2 more
Completed
2012-08past
2
Phase 3Liposomal amphotericin B
Invasive Fungal Disease
Completed
2013-12past
1
Phase 3Sofosbuvir
Hepatitis C
Completed
2014-03past
1
Phase 3SOF/VEL/VOX
Hepatitis C
Completed
2016-10-10past
1
Phase 3E/C/F/TAF
HIV+3 more
Completed
2017-09-14past
2
Phase 3Idelalisib
Chronic Lymphocytic Leukemia+7 more
Completed
2018-05-02past
4
Phase 3LDV/SOF
Chronic Hepatitis C Virus+4 more
Completed
2018-06-15past
7
Phase 3Remdesivir
COVID-19
Completed
2020-04-09past
1
Phase 3SOF/VEL
Hepatitis C Virus Infection
Completed
2021-03-26past
3
Phase 3Filgotinib
Rheumatoid Arthritis+2 more
Completed
2022-10past
4
Phase 3Magrolimab
Myelodysplastic Syndromes
Terminated
2023-09-13past
1
Phase 3Obeldesivir
COVID-19
Completed
2023-11-28past
1
Phase 2Bictegravir
HIV-1-infection
Active, not recruiting
2025-09-29past
1
Phase 3TAF
HBeAg-positive Chronic Hepatitis B+2 more
Recruiting
2026-09
3
Phase 2Lenacapavir
HIV-1-infection+1 more
Active, not recruiting
2030-07
2
Phase 3Seladelpar
Primary Biliary Cholangitis
Recruiting
2030-08
1
Phase 2Unnamed
Lymphoma
Unknown—1
Phase 1veltuzumab
Non-Hodgkin's Lymphoma+2 more
Completed
2007-11past
1
Phase 2AmBisome
Fungus Diseases
Completed
2009-01past
1
Phase 2placebo
HCV Infection
Completed
2009-07past
1
Phase 2GS-9450
Nonalcoholic Steatohepatitis
Completed
2009-08past
1
Phase 2MBX-102
Type 2 Diabetes Mellitus
Terminated
2010-02past
1
Phase 2FTC/RPV/TDF
HIV-1 Infection
Completed
2011-07past
1
Phase 2Cicletanine
Pulmonary Arterial Hypertension
Terminated
2011-10past
1
Phase 2Arhalofenate
Hyperuricemia+1 more
Completed
2011-10past
1
Phase 2GS-9190
Chronic Hepatitis C Infection
Completed
2013-01past
1
Phase 2D/C/F/TAF
Acquired Immunodeficiency Syndrome+1 more
Completed
2013-01past
1
Phase 2SOF
Hepatitis C
Completed
2013-09past
1
Phase 2GS-1101
Chronic Lymphocytic Leukemia
Withdrawn
2014-12past
1
Phase 1milatuzumab
Multiple Myeloma+9 more
Completed
2015-03past
2
Phase 2FTC/TDF
Chronic Hepatitis B
Completed
2015-11past
2
Phase 2IMMU-132 infusion is administered to participants in one arm for the study
Triple-negative Breast Cancer
Withdrawn
2016-08past
1
Phase 2Eleclazine
Ventricular Arrhythmia
Completed
2016-09past
1
Phase 1Veltuzumab and 90Y-Epratuzumab Tetraxetan
Non Hodgkin's Lymphoma+3 more
Withdrawn
2016-12past
1
Phase 2GS-4774
Chronic HBV Infection+1 more
Completed
2017-08-14past
2
Phase 2Selgantolimod
Chronic Hepatitis B
Completed
2019-03-22past
1
Phase 2Andecaliximab
Cystic Fibrosis+3 more
Completed
2019-10-25past
4
Phase 2SEL
Nonalcoholic Steatohepatitis
Completed
2019-10-30past
1
Phase 2GS-5718
Rheumatoid Arthritis
Withdrawn
2023-02past
1
Phase 2Teropavimab
HIV-1 Infection
Active, not recruiting
2024-07-02past
1
Phase 2Tirabrutinib
Chronic Spontaneous Urticaria+1 more
Terminated
2024-09-25past
2
Phase 2Lenacapavir Injection
Pre-Exposure Prophylaxis of HIV Infection
Active, not recruiting
2026-05past
1
Phase 2Tilpisertib Fosmecarbil
Ulcerative Colitis
Recruiting
2027-01
1
Phase 1hMN14 (labetuzumab)
Pancreatic Neoplasms
Completed—1
Phase 2Efavirenz
HIV Infections
Completed—1
Phase 1GS-6620
Hepatitis C, Chronic
Completed
2011-10past
1
Phase 1Velpatasvir
Chronic Hepatitis C Virus
Completed
2013-03-15past
1
Phase 1GS-5737
Cystic Fibrosis
Completed
2013-07past
1
Phase 1GS-5745 SC
Ulcerative Colitis
Completed
2014-10past
1
Phase 1GS-9901
Follicular Lymphoma+3 more
Terminated
2015-08past
1
Phase 1Voxilaprevir
HCV Infection
Completed
2016-03-04past
1
Phase 1Alobresib
Solid Tumors and Lymphomas
Completed
2017-10-11past
1
Phase 1Hu5F9-G4
Acute Myeloid Leukemia+1 more
Completed
2018-11past
1
Phase 1Bulevirtide (BLV)
Chronic Hepatitis D Infection
Completed
2024-07-18past
1
Phase 1GS-9911
Solid Tumors
Active, not recruiting
2026-12
1
Phase 1Cidofovir
Herpes Simplex+1 more
Completed—1
Phase 1Tenofovir disoproxil fumarate
HIV Infections
Unknown—1
N/AHepsera
Hepatitis B
Completed
2006-04past
1
N/AUnnamed
Cystic Fibrosis
Completed
2016-12past
1
N/AUnnamed
Hepatitis C, Chronic
Completed
2017-03-28past
1
N/AUnnamed
Hepatitis C, Chronic
Completed
2018-04-09past
1
N/ABulevirtide
Chronic Hepatitis D Infection
Active, not recruiting
2028-07
1
N/AAdefovir Dipivoxil
Chronic Hepatitis B
Approved For Marketing—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.